ArticleBiochemical genetics2026
CircGABRB2_006 Drives Malignant Progression and EMT in Papillary Thyroid Carcinoma via the miR-296-5p/FGFR1 Axis.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Circular RNAs (circRNAs) have emerged as important regulators of tumor progression; however, their roles in papillary thyroid carcinoma (PTC) remain incompletely understood. In this study, we investigated the expression, biological function, and molecular mechanism of circGABRB2_006 in PTC. CircGABRB2_006 was significantly upregulated in PTC tissues and cell lines and was associated with aggressive clinicopathological characteristics, including increased tumor number, larger tumor size, advanced TNM stage, and lymph node metastasis. Functional assays demonstrated that circGABRB2_006 promoted PTC cell proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), tumor growth, and pulmonary metastasis, whereas its silencing exerted the opposite effects. Mechanistically, circGABRB2_006 predominantly localized in the cytoplasm and acted as a molecular sponge for miR-296-5p, thereby relieving miR-296-5p-mediated repression of fibroblast growth factor receptor 1 (FGFR1). Rescue experiments further confirmed that the oncogenic effects of circGABRB2_006 were largely dependent on the miR-296-5p/FGFR1 axis. Collectively, these findings demonstrate that circGABRB2_006 drives malignant progression of PTC through the miR-296-5p/FGFR1 signaling axis, highlighting its potential as a biomarker and therapeutic target in PTC.
Indexed as
Identifiers
42496931What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.